Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers, and distribution partners digitally through ...
In 2025, we made significant strides towards advancing DrugSorb-ATR - a two-time U.S. Food and Drug Administration (FDA) Breakthrough Device - through the FDA De Novo submission process to reduce ...
Zemetra indicated profitability is contingent on "planned compound growth of VDR in the public sector throughout fiscal 2026, ...
4d
William Blair completely revamped how it rates AI companies. These 7 stocks emerged as the winners.
William Blair analysts revamped how they are rating AI stocks. In their new framework, seven stocks emerged as winners, while ...
Insmed (NASDAQ:INSM) reported top-line results from its phase III ENCORE trial evaluating ARIKAYCE in adults with ...
Received FDA approval to expand fully implanted Acclaim Cochlear Implant Pivotal Clinical Trial to final stageStrengthened balance sheet by extinguishing $32 million in debtSubsequent to year-end, ...
Full-year gross margins Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in November Implemented Strategic Workforce and Cost Reduction Program ...
Dogecoin price slipped 4.26% over the past 24 hours to trade near $0.0927, mirroring a mild pullback across the broader ...
You have full access to this article via your institution. Figure 1: a, Hematoxylin and eosin-stained histological sections demonstrate dilated cardiomyopathy induced by the tropomodulin transgene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results